ACFT Creatinine Toxicology
Performed on all samples. Testing requires 30 mL of urine without preservative.
Transportation Conditions: Refrigerate or Room Temperature (Stability: 7 days)
| Analyte | Units | Cut-off | Instrument/Method |
|---|---|---|---|
| Creatinine | mg/dL | 20 | Immunoassay |
ACFT Urine Multidrug Panel
Performed on all samples.
Note: alpha-Hydroxyethylbromazolam is currently being monitored, but not reported.
| Analyte | Units | Cut-off | Instrument/Method | Transportation Conditions |
|---|---|---|---|---|
| Buprenorphine | ng/mL | 10 | LC-MS/MS | N/A |
| Norbuprenorphine | ng/mL | 5 | LC-MS/MS | N/A |
| Methadone | ng/mL | 100 | LC-MS/MS | N/A |
| EDDP | ng/mL | 100 | LC-MS/MS | N/A |
| 6-Acetylmorphine (6-MAM) | ng/mL | 5 | LC-MS/MS | N/A |
| Codeine | ng/mL | 25 | LC-MS/MS | N/A |
| Morphine | ng/mL | 25 | LC-MS/MS | N/A |
| Hydrocodone | ng/mL | 25 | LC-MS/MS | N/A |
| Hydromorphone | ng/mL | 25 | LC-MS/MS | N/A |
| Oxycodone | ng/mL | 25 | LC-MS/MS | N/A |
| Noroxycodone | ng/mL | 25 | LC-MS/MS | N/A |
| Oxymorphone | ng/mL | 25 | LC-MS/MS | N/A |
| Thebaine | ng/mL | 25 | LC-MS/MS | N/A |
| Tramadol | ng/mL | 25 | LC-MS/MS | N/A |
| O-desmethyl-cis-Tramadol | ng/mL | 25 | LC-MS/MS | N/A |
| Fentanyl | ng/mL | 2 | LC-MS/MS | N/A |
| Norfentanyl | ng/mL | 2 | LC-MS/MS | N/A |
| Carfentanil | ng/mL | 2 | LC-MS/MS | N/A |
| Norcarfentanil | ng/mL | 2 | LC-MS/MS | N/A |
| ortho-Methylfentanyl | ng/mL | 2 | LC-MS/MS | N/A |
| para-Flurofentanyl | ng/mL | 2 | LC-MS/MS | N/A |
| Xylazine | ng/mL | 10 | LC-MS/MS | N/A |
| Medetomidine | ng/mL | 2 | LC-MS/MS | N/A |
| 3-Hydroxymedetomidine | ng/mL | 5 | LC-MS/MS | N/A |
| Ketamine | ng/mL | 1 | LC-MS/MS | N/A |
| Norketamine | ng/mL | 5 | LC-MS/MS | N/A |
| Amphetamine | ng/mL | 25 | LC-MS/MS | N/A |
| Methamphetamine | ng/mL | 25 | LC-MS/MS | N/A |
| MDA | ng/mL | 50 | LC-MS/MS | N/A |
| MDMA | ng/mL | 25 | LC-MS/MS | N/A |
| Benzoylecgonine | ng/mL | 25 | LC-MS/MS | N/A |
| 7-Aminoclonazepam | ng/mL | 10 | LC-MS/MS | N/A |
| 7-Aminonitrazepam | ng/mL | 10 | LC-MS/MS | N/A |
| alpha-Hydroxyalprazolam | ng/mL | 10 | LC-MS/MS | N/A |
| alpha-Hydroxytriazolam | ng/mL | 10 | LC-MS/MS | N/A |
| Bromazepam | ng/mL | 10 | LC-MS/MS | N/A |
| Bromazolam | ng/mL | 10 | LC-MS/MS | N/A |
| alpha-Hydroxybromazolam | ng/mL | 10 | LC-MS/MS | N/A |
| Demoxepam | ng/mL | 10 | LC-MS/MS | N/A |
| 3-Hydroxydesalkylgidazepam | ng/mL | 10 | LC-MS/MS | N/A |
| Diazepam | ng/mL | 10 | LC-MS/MS | N/A |
| Ethylbromazolam | ng/mL | 10 | LC-MS/MS | N/A |
| alpha-Hydroxyethylbromazolam | ng/mL | 25 | LC-MS/MS | N/A |
| Ethylflualprazolam | ng/mL | 10 | LC-MS/MS | N/A |
| Etizolam | ng/mL | 10 | LC-MS/MS | N/A |
| alpha-Hydroxyetizolam | ng/mL | 10 | LC-MS/MS | N/A |
| Flualprazolam | ng/mL | 10 | LC-MS/MS | N/A |
| alpha-Hydroxyflualprazolam | ng/mL | 10 | LC-MS/MS | N/A |
| Flubromazepam | ng/mL | 10 | LC-MS/MS | N/A |
| 3-Hydroxyflubromazepam | ng/mL | 10 | LC-MS/MS | N/A |
| alpha-Hydroxyflubromazolam | ng/mL | 10 | LC-MS/MS | N/A |
| Lorazepam | ng/mL | 10 | LC-MS/MS | N/A |
| 1-Hydroxymidazolam | ng/mL | 10 | LC-MS/MS | N/A |
| Norclobazam | ng/mL | 10 | LC-MS/MS | N/A |
| Nordiazepam | ng/mL | 10 | LC-MS/MS | N/A |
| Oxazepam | ng/mL | 10 | LC-MS/MS | N/A |
| Temazepam | ng/mL | 10 | LC-MS/MS | N/A |
| Diphenhydramine | ng/mL | 10 | LC-MS/MS | N/A |
| Gabapentin | ng/mL | 200 | LC-MS/MS | N/A |
| Ritalinic acid | ng/mL | 200 | LC-MS/MS | N/A |
| Methylphenidate | ng/mL | 25 | LC-MS/MS | N/A |
| Zolpidem | ng/mL | 25 | LC-MS/MS | N/A |
| Zolpidem Phenyl-4-carboxylic acid | ng/mL | 25 | LC-MS/MS | N/A |
| Zopiclone | ng/mL | 25 | LC-MS/MS | N/A |
| N-desmethylzopiclone | ng/mL | 25 | LC-MS/MS | N/A |
Confirmatory and Other Testing
Performed as required or as requested.
| Analyte | Units | Cut-off | Instrument/Method | Transportation Conditions |
|---|---|---|---|---|
| Ethanol | mg/dL | 20 | GC-FID | N/A |
| Nitazenes | N/A | N/A | Q-Exactive (Qualitative analysis only) | Refrigerate or Room Temperature Stability: 7 days |
Discontinued Testing
| Analyte | Units | Cut-off | Instrument/Method | Discontinued Date |
|---|---|---|---|---|
| Methadone in serum | ng/mL | 50 | LC-MS/MS | October 2024 |
| EDDP in serum | ng/mL | 50 | LC-MS/MS | October 2024 |
| Alprazolam | ng/mL | 50 | LC-MS/MS | December 2024 |
| Clobazam | ng/mL | 50 | LC-MS/MS | December 2024 |
| Flubromazolam | ng/mL | 50 | LC-MS/MS | December 2024 |
| Midazolam | ng/mL | 50 | LC-MS/MS | December 2024 |
| Amphetamines | ng/mL | 500 | Immunoassay | April 2026 |
| Benzodiazepines | ng/mL | 200 | Immunoassay | April 2026 |
| Buprenorphine | ng/mL | 10 | Immunoassay | April 2026 |
| Cocaine | ng/mL | 150 | Immunoassay | April 2026 |
| EDDP | ng/mL | 300 | Immunoassay | April 2026 |
| Ethanol | mg/dL | 20 | Immunoassay | April 2026 |
| Fentanyl | ng/mL | 2 | Immunoassay | April 2026 |
| Opiates | ng/mL | 300 | Immunoassay | April 2026 |
| Oxycodone | ng/mL | 100 | Immunoassay | April 2026 |
| Glucose | mg/dL | 50 - 100 | Test Strip | April 2026 |
| Ethyl Glucuronide | ng/mL | 250 | Q-Trap LC-MS/MS | April 2026 |
| Ethyl Sulfate | ng/mL | 200 | Q-Trap LC-MS/MS | April 2026 |
| Gamma Hydroxybutyrate | µg/mL | 10 | Q-Trap LC-MS/MS | April 2026 |
| 4-Hydroxyxylazine | ng/mL | 50 | LC-MS/MS | June 2026 |
